A New Era in HIV Prevention: The Long-Acting Power of Lenacapavir
Bibliographic record
Abstract
Lenacapavir (LEN) is a groundbreaking first-in-class HIV-1 capsid inhibitor developed by Gilead sciences and marketed as Sun Lenca in both tablet and subcutaneous injection forms. It has been approved by major regulatory agencies, including the US FDA, EMA, and Health Canada, for the treatment of multidrug-resistant (MDR) HIV-1 infections, which remain a critical unmet medical need. LEN is administered twice yearly via subcutaneous injection has been proven effective for HIV prevention in cisgender women and men; its effectiveness in cisgender men, transgender women, transgender men, and gender-nonbinary individuals remains uncertain. The unique mechanism of action targeting the HIV-1 capsid makes LEN highly effective against MDR strains, with minimal drug-related mutation and non-cross-resistance to other classes of anti-retro viral agents. LEN is especially suitable for patients with limited health care access due to its long-acting profile and ease of administration. Pharmacologically, LEN exhibits additive or synergistic effects when combined with antiretroviral agents as rilpivirine, cabotegravir, islatravir, bictegravir and tenofovir. However, HIV management is often complicated by opportunistic infections like TB, emphasizing need for comprehensive drug-drug, drug-food, and drug-disease interaction studies. Patient literature reveals ongoing research on innovative LEN-based formulations and combination therapies, particularly targeting HIV and TB coinfections in a single dosage form. Future developments aim to optimize LEN’s pharmacokinetic properties, expand its clinical use, and enhance patient outcomes. LEN represents a major advancement in treatment and prevention of MDR HIV-1 infection, with significant potential for further therapeutic innovation.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.002 | 0.003 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.004 |
| Insufficient payload (model declined to judge) | 0.009 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".